Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03233399

Modulating Movement Intention Via Cortical Stimulation

The purpose of this protocol is to learn about movement intention and volition. To improve such knowledge, investigators will conduct sub-studies using multiple non-invasive methodologies. These results could provide preliminary data for subsequent studies evaluating local and global efficacy of plasticity-inducing treatments for PMD symptoms.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

New York University School of Medicine

New York, 10016, United States

Location status: Recruiting

Location contact

Biyu He, MD

PRINCIPAL_INVESTIGATOR

Steven Stork

CONTACT

[email protected]

212-263-0001

About this study

This study will:

  • Explore effects of TMS and tDCS on movement intention.
  • Discern the neural activity underlying modulation of movement intention with neuroimaging recording.
  • Identify brain stimulation's effect in patients with psychogenic tremor and non-epileptic seizures.
  • Technical development of new experimental paradigms and data analysis methods.
  • Data collection for hypotheses development.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

(Healthy Controls)

  • Fluent in English

(Patients with PMD or PNES):

  • Diagnosis of PMD/PNES confirmed by a neurologist with expertise in movement disorders.
  • Per the treating neurologist, subject is unlikely to require treatment and/or dosage changes for 3-6 months following screening

Exclusion criteria

  • Any history of a significant neurological disorder, which may interfere with the interpretation of study data, as determined by the PI
  • Chronic or progressive medical condition
  • Any history of traumatic brain injury or significant head trauma
  • Currently meets criteria for substance abuse or dependence
  • History of any psychotic disorder or other psychiatric condition which may interfere with data interpretation
  • Pregnancy
  • Metal or devices in the head, including neurostimulators or metal foreign bodies
  • Any other implanted metal device, including pacemaker, spinal cord stimulator, VNS.
  • Any other ferromagnetic substance in the body that may increase study risk (including dental prosthetics, etc.).
  • Taking tricyclic antidepressant or antiepileptic medications or CNS active drugs under "strong potential hazard" list in Rossi et al., 2009
  • Current diagnosis of any inflammatory or autoimmune disorder within last 6 months

PMD and PNES Patients

  • Any history of traumatic brain injury or significant head trauma
  • Diagnosis of organic seizure disorder, including febrile seizures and tonic-clonic seizures;
  • Neurological disorder other than PMD and PNES including stroke, fainting spells or syncope of unknown cause(s);
  • Major or unstable medical illness, especially any current diagnosis of inflammatory or autoimmune disorders within last 6 months
  • Metal or devices in the head, including neurostimulators or metal foreign bodies
  • Taking tricyclic antidepressant medications or CNS active drugs under "strong potential hazard" list in Rossi et al., 2009;
  • Diagnosis of dementia, or Montreal Cognitive Assessment (MoCA) ≤24;
  • Recurrent visual hallucinations, within the past 6 months;
  • History of significant uncontrollable movements of the head;
  • Any clinically significant abnormality on vital signs

Treatment and study plan

Sham TMS3 stimulation

Device

half of the subjects will receive sham stimulation first

rTMS of left or right angular gyrus (AG) or frontal cortex (FC)

Device

Half of the subjects will receive active stimulation first; A subject may receive either TMS or tDCS stimulation, but not both, over the course of the sub-study.

Other names: 45 Minutes

Anodal tDCS of left or right AG or FC

Device

Half of the subjects will receive active stimulation first; A subject may receive either TMS or tDCS stimulation, but not both, over the course of the sub-study.

Other names: 30 Minutes

Primary outcomes

  1. Changes in signal intensity measured using of tDCS

    Time frame: 30 Minutes

    as a result of altering cerebral perfusion in response to neurophysiologic stimulation

  2. Changes in signal intensity measured during EEG recording

    Time frame: 3 Hours

    as a result of altering cerebral perfusion in response to neurophysiologic stimulation

  3. Changes in signal intensity measured during MEG

    Time frame: 3 Hours

    as a result of altering cerebral perfusion in response to neurophysiologic stimulation

Study contacts

Contact information is provided by the study sponsor or research team.

Nalini Jeet

CONTACT

[email protected]

(212) 263-0228

Sponsors and collaborators

Lead sponsor

NYU Langone Health

Other

Registry information

Official study title

Modulating Movement Intention Via Cortical Stimulation in Healthy Subjects and Patients With Psychogenic Movement Disorders and Non-epileptic Seizures

Important dates

Study start
2017
Primary completion
2027
Study completion
2027
First posted
Jul 28, 2017
Registry last updated
Nov 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.